Thomas Powles
Impact in
Papers in
- Co-authors
- Joaquim Bellmunt (40 shared papers)Daniel S. Chen (5 shared papers)Nicholas J. Vogelzang (12 shared papers)Yohann Loriot (39 shared papers)Daniel Peter Petrylak (28 shared papers)Daniel Castellano (27 shared papers)Gregg Daniel Fine (8 shared papers)Priti S. Hegde (5 shared papers)
- Journals
- Annals of Oncology (61 papers)European Urology (32 papers)Journal of Clinical Oncology (26 papers)European Urology Oncology (12 papers)New England Journal of Medicine (12 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Thomas Powles
332 papers receiving 33.9k citations
Thomas Powles's Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 14.1k
- Surgery 13.9k
- Pulmonary and Respiratory Medicine 7.6k
- Immunology 4.7k
- Cancer Research 3.0k
Countries citing papers authored by Thomas Powles
This map shows the geographic impact of Thomas Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Powles more than expected).
Fields of papers citing papers by Thomas Powles
This network shows the impact of papers produced by Thomas Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Powles. The network helps show where Thomas Powles may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Powles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 347 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Hit paper breakdown → | 2018 | 4038 |
| 2 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Hit paper breakdown → | 2014 | 2018 |
| 3 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 1811 |
| 4 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 5 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 6 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1141 |
| 7 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 1080 |
| 8 | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 1079 |
| 9 | A Consensus Molecular Classification of Muscle-invasive Bladder Cancer Hit paper breakdown → | 2019 | 957 |
| 10 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 876 |
| 11 | COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Hit paper breakdown → | 2020 | 855 |
| 12 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2017 | 737 |
| 13 | The cancer-immunity cycle: Indication, genotype, and immunotype Hit paper breakdown → | 2023 | 627 |
| 14 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 609 |
| 15 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma Hit paper breakdown → | 2021 | 495 |
| 16 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 488 |
| 17 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 467 |
| 18 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 457 |
| 19 | COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Hit paper breakdown → | 2020 | 443 |
| 20 | Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2020 | 353 |
About Thomas Powles
Thomas Powles is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Immunology, having authored 347 papers that have together received 34.6k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (196 papers), Cancer Immunotherapy and Biomarkers (79 papers), Urinary and Genital Oncology Studies (63 papers), Renal cell carcinoma treatment (60 papers), Testicular diseases and treatments (20 papers), Cancer Genomics and Diagnostics (17 papers), Renal and related cancers (12 papers) and Prostate Cancer Treatment and Research (12 papers). The work is most often cited by research in Oncology (14.1k citations), Surgery (13.9k citations), Pulmonary and Respiratory Medicine (7.6k citations), Immunology (4.7k citations) and Cancer Research (3.0k citations). Thomas Powles has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Joaquim Bellmunt, Daniel S. Chen, Nicholas J. Vogelzang, Yohann Loriot, Daniel Peter Petrylak, Daniel Castellano, Gregg Daniel Fine, Priti S. Hegde, Ira Mellman and Noah M. Hahn. Their work appears in journals such as Annals of Oncology, European Urology, Journal of Clinical Oncology, European Urology Oncology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.